Tag archive for ‘Amylin acquisition’
Amylin Acquisition is a Mild Positive for Bristol-Myers Squibb
I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could be quite […]